Form 4: Protagonist Therapeutics CFO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Asif Ali, Chief Financial Officer of Protagonist Therapeutics, Inc, sold 58,629 shares of common stock on September 30, 2026.

Summary

  • Option exercise/conversion: acquired 9,229 Common Stock at $38.98 ($359,746) on September 30, 2026; holds 68,232 after (Direct).
  • Option exercise/conversion: acquired 28,438 Common Stock at $23.42 ($666,018) on September 30, 2026; holds 96,670 after (Direct).
  • Option exercise/conversion: acquired 15,650 Common Stock at $19.19 ($300,324) on September 30, 2026; holds 112,320 after (Direct).
  • Option exercise/conversion: acquired 5,312 Common Stock at $12.17 ($64,647) on September 30, 2026; holds 117,632 after (Direct).
  • Open-market sale: disposed of 12,595 Common Stock at $141.77 ($1,785,593) on September 30, 2026; holds 105,037 after (Direct).
  • Open-market sale: disposed of 46,034 Common Stock at $141.78 ($6,526,701) on September 30, 2026; holds 59,003 after (Direct).
  • Option exercise/conversion: disposed of 9,229 Stock Option (right to buy) on September 30, 2026; holds 29,291 after (Direct).
  • Option exercise/conversion: disposed of 28,438 Stock Option (right to buy) on September 30, 2026; holds 49,562 after (Direct).
  • Option exercise/conversion: disposed of 15,650 Stock Option (right to buy) on September 30, 2026; holds 51,150 after (Direct).
  • Option exercise/conversion: disposed of 5,312 Stock Option (right to buy) on September 30, 2026; holds 25,235 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $8,312,294 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Asif Ali — Officer (Chief Financial Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-30Option exercise/conversionCommon Stock9,229$39$359.7K68,232
2026-09-30Option exercise/conversionCommon Stock28,438$23$666.0K96,670
2026-09-30Option exercise/conversionCommon Stock15,650$19$300.3K112,320
2026-09-30Option exercise/conversionCommon Stock5,312$12$64.6K117,632
2026-09-30Open-market saleCommon Stock12,595$142$1.8M105,037
2026-09-30Open-market saleCommon Stock46,034$142$6.5M59,003
2026-09-30Option exercise/conversionStock Option (right to buy)9,229——29,291
2026-09-30Option exercise/conversionStock Option (right to buy)28,438——49,562
2026-09-30Option exercise/conversionStock Option (right to buy)15,650——51,150
2026-09-30Option exercise/conversionStock Option (right to buy)5,312——25,235

Key Dates

DateDescription
2026-09-30Option exercise/conversion (9,229 shares)
2026-09-30Option exercise/conversion (28,438 shares)
2026-09-30Option exercise/conversion (15,650 shares)
2026-09-30Option exercise/conversion (5,312 shares)
2026-09-30Open-market sale (12,595 shares)
2026-09-30Open-market sale (46,034 shares)
2026-09-30Option exercise/conversion (9,229 shares)
2026-09-30Option exercise/conversion (28,438 shares)
2026-09-30Option exercise/conversion (15,650 shares)
2026-09-30Option exercise/conversion (5,312 shares)

Keywords

insider transaction, Form 4, PTGX, Protagonist Therapeutics, Inc, bearish, Asif Ali

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.